# Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain

> **NCT07013760** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 420 (actual)

## Conditions studied

- Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07013760
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-23
- **Primary completion:** 2025-12-19
- **Final completion:** 2025-12-19
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013760, "Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07013760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*